Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
Brigham and Women's Hospital- 221 Longwood Avenue, Boston, Massachusetts, United States
Northwestern University, Chicago, Illinois, United States
Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States
Dept. of Anesthesiology, Pharmacology & Therapeutics (APT), University of British Columbia, Vancouver, British Columbia, Canada
Children's National Medical Center, Washington, District of Columbia, United States
Ajou University Medical Center, Suwon, Gyeonggi, Korea, Republic of
Children's Mercy Hospital, Kansas City, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.